论文部分内容阅读
目的探讨不同剂量米非司酮治疗子宫肌瘤的疗效。方法选取2014年4月至2015年4月间三亚市中医院收治的96例子宫肌瘤患者,采用随机数字表法将患者随机分为大剂量组和小剂量组,每组48例。大剂量组患者采用口服25 mg米非司酮,每天1次。小剂量组患者采用口报12.5 mg米非司酮,每天1次。比较两组患者的疗效。结果两组患者治疗后总有效率的差异无统计学意义(P>0.05)。大剂量组患者药物不良反应显著高于小剂量组,差异有统计学意义(P<0.05)。小剂量组患者治疗后,卵泡生成激素(FSH)、黄体生成激素(LH)、雌二醇(E2)和孕酮(P)水平显著低于大剂量组,差异有统计学意义(P<0.05)。小剂量组患者治疗后行经期和月经量显著高于大剂量组,差异有统计学意义(P<0.05)。结论口服12.5 mg米非司酮,每天1次,是治疗子宫肌瘤安全、有效的剂量。
Objective To investigate the efficacy of different doses of mifepristone in the treatment of uterine fibroids. Methods A total of 96 patients with uterine leiomyoma admitted from April 2014 to April 2015 in Sanya Hospital of Traditional Chinese Medicine were randomly divided into high-dose group and low-dose group, with 48 patients in each group. Patients in the high-dose group received oral mifepristone 25 mg once daily. Patients in the low-dose group reported oral mifepristone 12.5 mg once daily. Compare the efficacy of two groups of patients. Results There was no significant difference in the total effective rate between the two groups after treatment (P> 0.05). Adverse drug reactions in the high-dose group were significantly higher than those in the low-dose group, the difference was statistically significant (P <0.05). The levels of FSH, LH, E2 and progesterone in the low-dose group were significantly lower than those in the high-dose group after treatment (P <0.05 ). The patients in low-dose group had significantly higher menstrual flow and menstrual flow than those in high-dose group after treatment (P <0.05). Conclusions Oral 12.5 mg mifepristone, once daily, is a safe and effective dose for the treatment of uterine fibroids.